Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1928 1
1933 2
1947 1
1948 1
1952 1
1954 1
1955 1
1956 2
1957 4
1958 3
1959 2
1960 2
1961 2
1963 4
1964 8
1965 4
1966 2
1967 1
1968 5
1969 4
1970 6
1971 2
1972 8
1973 3
1974 2
1975 4
1976 10
1977 7
1978 8
1979 6
1980 11
1981 11
1982 14
1983 15
1984 23
1985 14
1986 21
1987 39
1988 43
1989 75
1990 78
1991 57
1992 37
1993 43
1994 37
1995 59
1996 55
1997 53
1998 60
1999 51
2000 65
2001 84
2002 75
2003 65
2004 74
2005 69
2006 78
2007 96
2008 104
2009 124
2010 144
2011 149
2012 146
2013 180
2014 134
2015 212
2016 184
2017 178
2018 206
2019 232
2020 253
2021 297
2022 298
2023 294
2024 117

Text availability

Article attribute

Article type

Publication date

Search Results

4,294 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of three agility tests with male servicemembers: Edgren Side Step Test, T-Test, and Illinois Agility Test.
Raya MA, Gailey RS, Gaunaurd IA, Jayne DM, Campbell SM, Gagne E, Manrique PG, Muller DG, Tucker C. Raya MA, et al. Among authors: muller dg. J Rehabil Res Dev. 2013;50(7):951-60. doi: 10.1682/JRRD.2012.05.0096. J Rehabil Res Dev. 2013. PMID: 24301432 Free article.
A good positive relationship exists between the IAT and T-Test (r = 0.76, p < 0.001) and a moderate negative relationship exists between the ESST and both the T-Test (r = -0.69, p < 0.001) and IAT (r = -0.65, p < 0.001). ...

A good positive relationship exists between the IAT and T-Test (r = 0.76, p < 0.001) and a moderate negative relationship exists b

…
Adenosine A(2A)R/A(1)R Antagonists Enabling Additional H(3)R Antagonism for the Treatment of Parkinson's Disease.
Hagenow S, Affini A, Pioli EY, Hinz S, Zhao Y, Porras G, Namasivayam V, Müller CE, Lin JS, Bezard E, Stark H. Hagenow S, et al. Among authors: muller ce. J Med Chem. 2021 Jun 24;64(12):8246-8262. doi: 10.1021/acs.jmedchem.0c00914. Epub 2021 Jun 9. J Med Chem. 2021. PMID: 34107215
Adenosine A(1)/A(2A) receptors (A(1)R/A(2A)R) represent targets in nondopaminergic treatment of motor disorders such as Parkinson's disease (PD). ...Recognizing the wake-promoting capacity of histamine H(3) receptor (H(3)R) antagonists in combination with the …
Adenosine A(1)/A(2A) receptors (A(1)R/A(2A)R) represent targets in nondopaminergic treatment of motor disorders such as Parkin …
Tools and drugs for uracil nucleotide-activated P2Y receptors.
Rafehi M, Müller CE. Rafehi M, et al. Among authors: muller ce. Pharmacol Ther. 2018 Oct;190:24-80. doi: 10.1016/j.pharmthera.2018.04.002. Epub 2018 Apr 13. Pharmacol Ther. 2018. PMID: 29660366 Review.
Several potent P2Y(6)R agonists have been developed including 5-methoxyuridine 5'-O-((R(p))alpha-boranodiphosphate) (6-12), PSB-0474 (3-11), and MRS2693 (3-26). ...With MRS2905 (6-08), a potent and metabolically stable P2Y(14)R agonist is available, while PPT …
Several potent P2Y(6)R agonists have been developed including 5-methoxyuridine 5'-O-((R(p))alpha-boranodiphosphate) (6-12), PS …
Attempted reduction of a carbazolyl-diiodoalane.
Hinz A, Müller MP. Hinz A, et al. Among authors: muller mp. Chem Commun (Camb). 2021 Nov 23;57(93):12532-12535. doi: 10.1039/d1cc05557g. Chem Commun (Camb). 2021. PMID: 34751692
The use of KC(8) allowed the spectroscopic observation of the alanediyl [R-Al]. With Cp*(2)Co as the reducing agent, the alanediyl [R-Al] was obtained as a crystalline material in low yield, but paramagnetic impurities remained. When diiodoalane [R-AlI(2)] wa …
The use of KC(8) allowed the spectroscopic observation of the alanediyl [R-Al]. With Cp*(2)Co as the reducing agent, the alanediyl [ …
Structure-Based Design of High-Affinity Fluorescent Probes for the Neuropeptide Y Y1 Receptor.
Müller C, Gleixner J, Tahk MJ, Kopanchuk S, Laasfeld T, Weinhart M, Schollmeyer D, Betschart MU, Lüdeke S, Koch P, Rinken A, Keller M. Müller C, et al. J Med Chem. 2022 Mar 24;65(6):4832-4853. doi: 10.1021/acs.jmedchem.1c02033. Epub 2022 Mar 9. J Med Chem. 2022. PMID: 35263541
The recent crystallization of the neuropeptide Y Y(1) receptor (Y(1)R) in complex with the argininamide-type Y(1)R selective antagonist UR-MK299 (2) opened up a new approach toward structure-based design of nonpeptidic Y(1)R ligands. We designed novel fluores …
The recent crystallization of the neuropeptide Y Y(1) receptor (Y(1)R) in complex with the argininamide-type Y(1)R selective a …
Cytomegalovirus Donor Seropositivity Negatively Affects Survival After Heart Transplantation.
Heim C, Müller PP, Tandler R, Cherikh WS, Toll AE, Stehlik J, Weyand M, Khush KK, Ensminger SM. Heim C, et al. Among authors: muller pp. Transplantation. 2022 Jun 1;106(6):1243-1252. doi: 10.1097/TP.0000000000003961. Epub 2022 Sep 23. Transplantation. 2022. PMID: 34560698
Posttransplant survival and risk of developing CAV were compared across 4 groups: CMV-seronegative recipients (R-) receiving CMV-positive grafts (D+), intermediate-risk patients (D+R+ and D-R+), and low-risk patients (D-R-). ...Kaplan-Meier survival an …
Posttransplant survival and risk of developing CAV were compared across 4 groups: CMV-seronegative recipients (R-) receiving CMV-posi …
Extracellular and intracellular proteases in cardiac dysfunction due to ischemia-reperfusion injury.
Müller AL, Hryshko LV, Dhalla NS. Müller AL, et al. Int J Cardiol. 2013 Mar 20;164(1):39-47. doi: 10.1016/j.ijcard.2012.01.103. Epub 2012 Feb 20. Int J Cardiol. 2013. PMID: 22357424 Review.
Various procedures such as angioplasty, thrombolytic therapy, coronary bypass surgery, and cardiac transplantation are invariably associated with ischemia-reperfusion (I/R) injury. Impaired recovery of cardiac function due to I/R injury is considered to be a consequ …
Various procedures such as angioplasty, thrombolytic therapy, coronary bypass surgery, and cardiac transplantation are invariably associated …
Boosted dopamine and blunted serotonin in Tourette syndrome - evidence from in vivo imaging studies.
Nikolaus S, Mamlins E, Antke C, Dabir M, Müller HW, Giesel FL. Nikolaus S, et al. Among authors: muller hw. Rev Neurosci. 2022 May 16;33(8):859-876. doi: 10.1515/revneuro-2022-0035. Print 2022 Dec 16. Rev Neurosci. 2022. PMID: 35575756 Review.
SERT was unaltered in midbrain/pons (MP), but decreased in PUT, thalamus (THAL) and hypothalamus. D(2)R was unaltered throughout the nigrostriatal and mesolimbocortical system, while DA release was not different from controls in PUT, CAUD and NSTR, but elevated in VSTR. 5- …
SERT was unaltered in midbrain/pons (MP), but decreased in PUT, thalamus (THAL) and hypothalamus. D(2)R was unaltered throughout the …
Analysis of the adiponectin paradox in healthy older people.
Walowski CO, Herpich C, Enderle J, Braun W, Both M, Hasler M, Müller MJ, Norman K, Bosy-Westphal A. Walowski CO, et al. Among authors: muller mj. J Cachexia Sarcopenia Muscle. 2023 Feb;14(1):270-278. doi: 10.1002/jcsm.13127. Epub 2022 Nov 18. J Cachexia Sarcopenia Muscle. 2023. PMID: 36401062 Free PMC article.

RESULTS: Higher adiponectin levels were associated with a lower SMI (r = -0.23, P < 0.01), BMC (r = -0.17, P < 0.05) and liver fat (r = -0.20, P < 0.05) in the total population and with higher muscle fat in women (r = 0.27, P < 0.01). By co

…

RESULTS: Higher adiponectin levels were associated with a lower SMI (r = -0.23, P < 0.01), BMC (r = -0.17, P < 0.05) and

…
Discovery of P2Y2 Receptor Antagonist Scaffolds through Virtual High-Throughput Screening.
Neumann A, Attah I, Al-Hroub H, Namasivayam V, Müller CE. Neumann A, et al. Among authors: muller ce. J Chem Inf Model. 2022 Mar 28;62(6):1538-1549. doi: 10.1021/acs.jcim.1c01235. Epub 2022 Mar 14. J Chem Inf Model. 2022. PMID: 35285230
Despite its potential as a novel drug target, only few P2Y(2)R antagonists have been developed so far, all of which suffer from severe drawbacks. ...Several novel antagonist scaffolds were discovered, and their binding modes at the human P2Y(2)R were analyzed by mol …
Despite its potential as a novel drug target, only few P2Y(2)R antagonists have been developed so far, all of which suffer from sever …
4,294 results